Indietro

Selezionare la regione

Azienda

Richiedi un consulto sulle cellule staminali

Per saperne di più

I nostri
trapianti

Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:

Immagine
Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:
Nr. Fonte Tipo di fonte Diagnosi Settore medico Anno di applicazione Terapia Paese Età del destinatario
401 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Spain 72
402 Apheresis Allogeneic Lymphoma Burkitt Histiocytic Sarcoma Hematology 2026 Standard Therapy Greece 12
403 Apheresis Allogeneic Acute Myelogenous Leukaemia Hematology 2026 Standard Therapy France 69
404 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2026 Standard Therapy USA 69
405 Apheresis Allogeneic Acute Myeloid Leukemia FLT3-ITD positive Hematology 2026 Standard Therapy Romania 11
406 Apheresis Allogeneic Myelofibrosis (MF) Hematology 2026 Standard Therapy Lithuania 67
407 Apheresis Allogeneic X-ALD (E 71.3) Hematology 2026 Standard Therapy Czechia 5
408 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 73
409 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 36
410 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 56
411 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 53
412 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ukraine 39
413 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 24
414 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 62
415 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 70
416 Apheresis Allogeneic Other Malignancy Hematology 2026 Standard Therapy USA 71
417 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 62
418 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 59
419 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 70
420 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 26
421 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 40
422 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 68
423 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 56
424 Apheresis Allogeneic Myelodysplastic/Myeloproliferative Neoplasms Hematology 2026 Standard Therapy Spain 65
425 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 63
426 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 58
427 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 44
428 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 61
429 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 54
430 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Poland 11
431 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2026 Standard Therapy USA 64
432 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Portugal 64
433 Apheresis autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 32
434 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 69
435 Apheresis allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 54
436 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 64
437 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 72
438 Apheresis autologous Peripheral T-cell Lymphoma Hematology 2026 Standard Therapy Germany 56
439 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 60
440 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
441 Apheresis autologous Anaplastic Large-Cell Lymphoma Hematology 2026 Standard Therapy Germany 47
442 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 60
443 Apheresis allogeneic Vexas-Syndrome with UBA1-Mutation Hematology 2026 Standard Therapy Germany 67
444 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 27
445 Apheresis allogeneic Primary Myelofibrosis PMF Hematology 2026 Standard Therapy Poland 57
446 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 48
447 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Switzerland 67
448 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 42
449 Apheresis allogeneic MPS-I: Hurler Syndrome Hematology 2026 Standard Therapy Russia 1
450 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 29
451 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 47
452 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 66
453 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 4
454 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
455 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 63
456 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Lithuania 40
457 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 68
458 Apheresis allogeneic Chronic Lymphocytic Leukemia Hematology 2026 Standard Therapy Netherlands 61
459 Apheresis allogeneic Acute Lymphoblastic leukemia Hematology 2026 Standard Therapy Germany 21
460 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 72
461 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 36
462 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 57
463 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Belgium 63
464 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy United Kingdom 54
465 Apheresis allogeneic Other Malignancy, Specify Hematology 2026 Standard Therapy USA 54
466 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 76
467 Apheresis allogeneic Myelodysplastic Disorders Hematology 2026 Standard Therapy France 73
468 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 75
469 Apheresis allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 47
470 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 68
471 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 40
472 Apheresis allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Macedonia 59
473 Apheresis allogeneic Combined Immunodeficiency Hematology 2026 Standard Therapy Belgium 4
474 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Australia 13
475 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 33
476 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 38
477 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Russian Federation 28
478 Apheresis allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Germany 58
479 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Austria 54
480 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 74
481 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy United Kingdom 20
482 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 57
483 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 69
484 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 64
485 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 56
486 Apheresis autologous Myeloma Hematology 2026 Standard Therapy Portugal 42
487 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 56
488 Apheresis Autologous T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 68
489 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 71
490 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
491 Apheresis Allogeneic T-Cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 24
492 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 67
493 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 62
494 Apheresis Autologous Plasma Cell Leukemia Hematology 2026 Standard Therapy Germany 43
495 Apheresis Autologous Mantle Cell Lymphoma Hematology 2026 Standard Therapy Germany 60
496 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
497 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
498 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 70
499 Apheresis Allogeneic Primary Myelopathic Polycythemia Hematology 2026 Standard Therapy Germany 67
500 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61